Global bond yields are staying elevated as central banks respond to persistent energy driven inflation. That keeps cash returns uncertain and makes reliable income from equities more appealing. Dividend Powerhouses with 3%+ yields and a track record of stable, well covered payout policies can offer a clearer source of cash flow. This article highlights three stocks from the Dividend Powerhouses screener that stand out on those qualities.

The three stocks covered below are only a starting sample from this Dividend Powerhouses idea. The full screen surfaced 1,868 more companies with similarly compelling income profiles that are not covered here. To identify and analyze the opportunities that best fit your income goals, head straight to the Dividend Powerhouses (3%+ Yield) screener.

CSL (ASX:CSL)

CSL is a global biopharmaceutical group that develops and manufactures plasma based therapies, vaccines and treatments for iron deficiency and kidney related conditions, with operations spanning Australia, the United States, Europe and Asia. It generates about US$10.9b from CSL Behring, US$2.4b from CSL Vifor and US$2.2b from CSL Seqirus. Plasma therapies remain the economic engine alongside vaccines and nephrology. The stock is a heavyweight in the healthcare income space, with a market cap of around A$64.5b.

Investors looking at CSL today see a rare mix of income and quality, but also real tension between short term pain and long term potential. The core plasma and vaccine businesses sit on a large global footprint and a strong product pipeline, including recent positive Phase 3b data for ANDEMBRY in children aged 2 to 11. At the same time, margins have been squeezed, debt is high and a one off loss of A$2.1b has raised questions about balance sheet risk. With earnings forecasts pointing higher while the dividend is not well covered and restructuring still working through the numbers, the real opportunity sits in understanding whether this is a temporary reset or something more structural that income focused investors cannot ignore.

CSL’s income story appears caught between squeezed margins and a sizeable global footprint, so the key question is whether earnings can comfortably support those payouts again. Get the full picture in the 2 key rewards and 4 important warning signs

Build your own dividend powerhouse shortlist

CSL and the other two stocks in this list all came out of a single Simply Wall St screener, but the real value for you is in setting your own rules. Use our flexible Screener to combine filters like income strength, balance sheet and risk, or start with any of our curated Investing Ideas for ready made shortlists.

Accenture (ACN)

Accenture helps large companies and governments run and modernize their operations, from cloud and AI projects to outsourcing, cybersecurity and business process services. It generated about US$22.3b from its Products clients, US$14.9b from Health & Public Service, US$13.8b from Financial Services, US$12.4b from Communications, Media & Technology and US$9.8b from Resources, showing a broad spread across the global economy. The stock is a heavyweight in IT services with a market cap of around US$108.2b.

Income focused investors may find Accenture interesting because it combines a roughly 3.8% dividend yield with solid profitability metrics and a long list of AI focused contracts and partnerships. At the same time, earnings dipped over the past year, revenue growth guidance sits in the low single digits and the business is reshaping an 799,000 strong workforce for an AI centric future, which adds real execution risk. The key consideration is whether that mix of yield, quality and AI exposure at a discounted P/E offers a patient entry point. It is also possible that it represents a value trap, depending on how AI reshapes consulting and outsourcing over the next few years.

Accenture’s AI story and 3.8% yield could be masking something investors are not fully pricing in. Review the full analysis report for Accenture to see what the current numbers might be hinting at next.

Novo Nordisk (CPSE:NOVO B)

Novo Nordisk is a global pharmaceutical group focused on obesity, diabetes care and rare diseases, with products ranging from GLP-1 treatments like Wegovy pill and Ozempic to smart insulin pens and hormone therapies. Almost all revenue currently comes from Diabetes and Obesity Care at about DKK 309b, with a smaller Rare Disease segment around DKK 20b. The company is a giant in European healthcare, with a market cap of roughly DKK 1,303b.

Income investors are paying close attention to Novo Nordisk because it combines a major position in GLP-1 obesity and diabetes treatments with a roughly 4% dividend yield and a share repurchase program of up to DKK 15b that runs through early 2027. At the same time, earnings growth has slowed compared with its own 5 year record, the dividend is not well covered by free cash flow and recent ZEUS trial setbacks plus ongoing GLP-1 advertising litigation with Eli Lilly show that the story is not risk free. The stock currently trades well below some fair value estimates and carries very high forecast returns on equity, but the mix of funding structure, non cash earnings and a relatively fresh management team means the quality of that value deserves closer scrutiny.

Novo Nordisk’s GLP-1 engine, 4% yield and buybacks could be hiding a very different earnings path from what headlines suggest. Get the full story in the full narrative for Novo Nordisk

Seeking Fresh Alternatives Before Others Do

New themes can gain momentum quickly, while older stories risk dropping out of focus. Explore fresh stock ideas that may be under the radar for now and consider them early.

• Identify steady cash generators before they attract wider attention by scanning the curated 3 dividend fortresses, which surfaces companies with robust income profiles and more resilient balance sheets.
• Explore the next wave of computing developments by reviewing the hand picked 24 quantum computing stocks, which focuses on specialists building the hardware and software behind emerging processing power.
• Research the companies supporting AI-related activity by checking the focused 56 AI infrastructure stocks, which highlights suppliers of chips, data centers and critical networking gear.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.